Article ID Journal Published Year Pages File Type
10886806 Drug Discovery Today 2005 7 Pages PDF
Abstract
Clear links between cancer and cellular signaling triggered by the insulin-like growth factor-I (IGF-I) receptor (IGF-IR) and its cognate ligands (IGF-I and IGF-II) have been reported throughout the past two decades. Experimental results suggest that the pharmaceutical targeting of this signaling pathway could be beneficial for the treatment of cancer. Here, more recent advances towards potentially clinically viable strategies to interfere with the function of IGF-IR will be discussed.
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Biotechnology
Authors
, ,